Nippon India Pharma Fund - Growth - Regular Plan

Other Plans and Options
  • (-0.43%)Nav, as on 06-12-2022

  • Previous Nav

  • Net Change on 06-12-2022

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Nippon India Pharma Fund-Growth Plan-Growth -1.21 4.81 -1.48 24.38 16.14 19.94
S&P BSE Health Care - TRI -2.32 3.50 -3.41 21.85 12.20 13.65
S&P BSE SENSEX - TRI 2.79 5.99 11.82 17.03 15.29 13.63

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 -1.48 24.38 16.14 1.94 4,786.92

Fund Holdings as on 30-November-2022

  • Sun Pharmaceutical Industries Limited

  • Cipla Limited

  • Dr. Reddy's Laboratories Limited

  • Lupin Limited

  • Abbott India Limited

  • Apollo Hospitals Enterprise Limited

  • Narayana Hrudayalaya Limited

  • Divi's Laboratories Limited

  • Torrent Pharmaceuticals Limited

  • Aurobindo Pharma Limited

  • Fortis Healthcare Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Zydus Lifesciences Limited

  • Pfizer Limited

  • Vijaya Diagnostic Centre Limited

  • Sanofi India Limited

  • Thyrocare Technologies Limited

  • Gland Pharma Limited

  • Ajanta Pharma Limited

  • Alkem Laboratories Limited

  • Indoco Remedies Limited

  • IPCA Laboratories Limited

  • Orchid Pharma Limited

  • Triparty Repo

  • GlaxoSmithKline Pharmaceuticals Limited

  • Jubilant Pharmova Limited

  • Global Health Limited

  • Rainbow Childrens Medicare Limited

  • Tarsons Products Limited

  • Healthcare Global Enterprises Limited

  • Syngene International Limited

  • MedPlus Health Services Limited

  • Cash Margin - CCIL

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Plastic Products

View More

Fund Manager

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 05-Jun-2004 and currently has an AUM of ₹4,786.92 crore. Nippon India Pharma Fund is benchmarked against S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended down ₹-1.26(-0.43%)yesterday to ₹289.6093.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan and Kinjal Desai.

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097